Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	659.84	594.35	391.57	549.91	285.12	262.13
Short-Term Investments	-	-	-	-	231.45	-
Cash & Short-Term Investments	659.84	594.35	391.57	549.91	516.56	262.13
Cash Growth	54.30%	51.79%	-28.79%	6.46%	97.07%	275.09%
Accounts Receivable	-	-	-	-	0.03	0.16
Other Receivables	21.91	49.17	3.09	2.75	9.06	-
Receivables	21.91	49.17	3.09	2.75	9.09	0.16
Restricted Cash	3.14	3.05	3.23	1.28	1.55	2
Other Current Assets	29.22	67.71	40.25	15.87	7.51	2.16
Total Current Assets	714.11	714.27	438.14	569.81	534.72	266.44
Property, Plant & Equipment	181.24	233.21	120.17	121.45	64.73	25.97
Goodwill	162.04	148.87	52.06	0.8	0.8	0.8
Other Intangible Assets	322.34	335.86	36.44	1.31	1.39	1.69
Long-Term Deferred Tax Assets	0.96	1.93	-	-	-	-
Other Long-Term Assets	14.43	14.45	6.89	7.92	8.72	3.69
Total Assets	1,400	1,449	653.7	701.29	610.35	298.59
Accounts Payable	13.94	21.61	3.95	4.59	2.82	1.07
Accrued Expenses	72.15	80.28	41.76	30.29	27.67	10.49
Current Portion of Long-Term Debt	8.92	0.11	0.04	0.1	0.09	1.07
Current Portion of Leases	11.53	22.11	6.12	5.95	-	-
Current Unearned Revenue	47.36	61.77	36.43	56.73	10	10
Other Current Liabilities	1.21	1.59	4.87	2.62	6.08	0.47
Total Current Liabilities	155.1	187.47	93.17	100.27	46.66	23.1
Long-Term Debt	11.9	0.68	1.1	0.54	0.63	11.41
Long-Term Leases	50.03	85.59	43.41	44.42	-	-
Long-Term Unearned Revenue	111.2	118.77	51.24	70.26	6.67	16.67
Long-Term Deferred Tax Liabilities	23.31	16.58	1.34	-	-	-
Other Long-Term Liabilities	1.03	4.73	-	-	13.45	5.38
Total Liabilities	352.58	413.82	190.26	215.48	67.41	56.56
Common Stock	0.01	0	0	0	0	-
Additional Paid-In Capital	2,981	2,474	1,431	1,125	943.14	7.31
Retained Earnings	-1,968	-1,431	-967.62	-639.56	-400.08	-213.6
Comprehensive Income & Other	34.09	-7.64	-	-	-0.13	-
Total Common Equity	1,047	1,035	463.44	485.81	542.94	-206.29
Shareholders' Equity	1,047	1,035	463.44	485.81	542.94	242.02
Total Liabilities & Equity	1,400	1,449	653.7	701.29	610.35	298.59
Total Debt	82.37	108.49	50.67	51.01	0.72	12.49
Net Cash (Debt)	577.46	485.86	340.89	498.91	515.84	249.64
Net Cash Growth	71.34%	42.52%	-31.67%	-3.28%	106.63%	335.00%
Net Cash Per Share	1.44	1.77	1.64	2.84	4.12	11.46
Filing Date Shares Outstanding	521.26	401.99	234.65	191.23	170.77	22.31
Total Common Shares Outstanding	491.8	396.8	234.27	191.02	170.27	22.31
Working Capital	559	526.8	344.97	469.55	488.06	243.34
Book Value Per Share	2.13	2.61	1.98	2.54	3.19	-9.24
Tangible Book Value	562.56	550.05	374.94	483.7	540.75	-208.78
Tangible Book Value Per Share	1.14	1.39	1.60	2.53	3.18	-9.36
Machinery	-	128.29	82.22	67.69	53.08	20.78
Construction In Progress	-	2.71	3.23	8.75	16.45	1.36
Leasehold Improvements	-	72.73	45.93	41.87	13.94	13.79

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q